Skip to main content
  • Sign in
    Welcome !
    My account
    Logout

Voyager Therapeutics, Inc. (VYGR) Stock Forecast 2025 - AI Price Prediction & Analysis

Voyager Therapeutics, Inc. (VYGR) AI Stock Price Forecast & Investment Analysis

Voyager Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading Voyager Therapeutics, Inc. interactive price chart and technical analysis...

Voyager Therapeutics, Inc. (VYGR) - Comprehensive Stock Analysis & Investment Research

Deep dive into Voyager Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Voyager Therapeutics, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Voyager Therapeutics, Inc.: Voyager Therapeutics, Inc. operates in the Life Sciences sector, making it an emerging small-cap investment.

Voyager Therapeutics, Inc. (Stock Symbol: VYGR) is a leading company in the Life Sciences sector , specifically operating within the Biological Products, (No Diagnostic Substances) industry.

The organization employs approximately 149 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Voyager Therapeutics, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Voyager Therapeutics, Inc.: With $42M in annual revenue and 2277.1% net margin, the company demonstrates exceptional profitability.

Annual Revenue: $42 million generating a 2277.1% net profit margin .

Market Capitalization: $293 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -66.8% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Voyager Therapeutics, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Accuracy scores show historical prediction reliability.

For Voyager Therapeutics, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Voyager Therapeutics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Voyager Therapeutics, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Voyager Therapeutics, Inc.: Strong free cash flow generation demonstrates developing operational efficiency.

Voyager Therapeutics, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company demonstrates robust operational efficiency through strong free cash flow generation of $1 million annually.

The company maintains a healthy 85.6% gross margin, indicating strong pricing power and operational efficiency.

Voyager Therapeutics, Inc. (VYGR) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Voyager Therapeutics, Inc. stock analysis.

Loading Voyager Therapeutics, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Voyager Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Voyager Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Voyager Therapeutics, Inc.: With a P/E ratio of 570.60, the market highly values future growth prospects.

P/E Ratio 570.60x
P/B Ratio 1.20x
Market Cap $293M
EPS $-1.86
Book Value/Share $4.17
Revenue/Share $0.73
FCF/Share $-2.95
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Voyager Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Voyager Therapeutics, Inc.: An ROE of -66.8% indicates room for improvement in shareholder value creation.

ROE -66.8%
ROA -30.7%
ROIC -46.8%
Gross Margin 85.6%
Operating Margin 963.4%
Net Margin 2277.1%
EBT Margin -224.5%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Voyager Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Voyager Therapeutics, Inc.: A current ratio of 1.68 shows adequate liquidity.

Current Ratio 1.68x
Quick Ratio 1.64x
D/E Ratio 0.49x
Financial Leverage 2.95x
Working Capital $171M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Voyager Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Voyager Therapeutics, Inc.: Free cash flow of $1M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $2M
Free Cash Flow $1M
Capital Spending $-1M
FCF/Sales 2.9%
CapEx/Sales 4.0%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Voyager Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Voyager Therapeutics, Inc.: An asset turnover of 0.14x suggests room for improvement in asset utilization.

Asset Turnover 0.14x
Receivables Turnover 14.2x
Fixed Assets Turnover 0.6x
Days Sales Outstanding 26 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Voyager Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Voyager Therapeutics, Inc.: With annual revenue of $42M, Voyager Therapeutics, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $42M
R&D Expense $118M
SG&A Expense $111M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 76%
Cash & Short-term Investments 74%
Total Liabilities 66%
Accounts Receivable 0%
Dividend & Shareholder Information
Shares Outstanding 59M
Growth Metrics (YoY)
EPS Growth 13.9%

Latest Voyager Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Voyager Therapeutics, Inc. (VYGR) stock price and investment outlook.

📰 We are currently updating our news feed for Voyager Therapeutics, Inc.. Check back soon for the latest market analysis and company updates.

Voyager Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Voyager Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS Unlock Forecast - 30 Days FREE Trial $130M -1.9x 1.1x
ABP Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
ACOG Unlock Forecast - 30 Days FREE Trial $112M x 3.5x
ADAP Unlock Forecast - 30 Days FREE Trial $294M -13.2x -11.8x
ADMA Unlock Forecast - 30 Days FREE Trial $3476M 16.6x 8.7x
ADPT Unlock Forecast - 30 Days FREE Trial $2551M -4.6x 14.2x
AGEN Unlock Forecast - 30 Days FREE Trial $119M -0.5x -0.5x
AIM Unlock Forecast - 30 Days FREE Trial $2M -0.5x -183.3x
AIMI Unlock Forecast - 30 Days FREE Trial $2M x x
ALEC Unlock Forecast - 30 Days FREE Trial $306M -1.2x 4.3x
ALGS Unlock Forecast - 30 Days FREE Trial $89M -19.2x 0.9x
ALLO Unlock Forecast - 30 Days FREE Trial $271M -1.4x 0.8x
AMGN Unlock Forecast - 30 Days FREE Trial $159235M 24.1x 21.4x
APGE Unlock Forecast - 30 Days FREE Trial $3178M -20.5x 4.3x
APTOF Unlock Forecast - 30 Days FREE Trial $3M x x
ARMP Unlock Forecast - 30 Days FREE Trial $115M -1.0x -1.6x
ARTV Unlock Forecast - 30 Days FREE Trial $68M x 0.5x
ATHA Unlock Forecast - 30 Days FREE Trial $150M -0.2x 4.7x
ATRA Unlock Forecast - 30 Days FREE Trial $166M 28.6x -1.1x
AURA Unlock Forecast - 30 Days FREE Trial $367M -4.9x 2.1x
AUTL Unlock Forecast - 30 Days FREE Trial $442M x 1.3x
AVXL Unlock Forecast - 30 Days FREE Trial $792M -17.3x 8.7x
BCLI Unlock Forecast - 30 Days FREE Trial $7M -4.9x -0.9x
BDTX Unlock Forecast - 30 Days FREE Trial $235M 16.3x 1.8x
BEAM Unlock Forecast - 30 Days FREE Trial $2617M -12.6x 2.5x
BIIB Unlock Forecast - 30 Days FREE Trial $20870M 13.6x 1.4x
CABA Unlock Forecast - 30 Days FREE Trial $212M -1.6x 1.2x
CCCC Unlock Forecast - 30 Days FREE Trial $160M -2.6x 0.9x
CELZ Unlock Forecast - 30 Days FREE Trial $9M -3.4x 1.3x
CERO Unlock Forecast - 30 Days FREE Trial $1M x -196.2x
CGEN Unlock Forecast - 30 Days FREE Trial $173M x 3.4x
CGON Unlock Forecast - 30 Days FREE Trial $3141M x 4.7x
CGTX Unlock Forecast - 30 Days FREE Trial $119M -0.5x 16.9x
CHRS Unlock Forecast - 30 Days FREE Trial $194M 1.1x 1.6x
CLDI Unlock Forecast - 30 Days FREE Trial $5M -0.9x 3.0x
CMPX Unlock Forecast - 30 Days FREE Trial $586M -4.8x 6.3x
CRBU Unlock Forecast - 30 Days FREE Trial $232M -1.5x 1.4x
CRDF Unlock Forecast - 30 Days FREE Trial $147M -4.0x 2.5x
CRIS Unlock Forecast - 30 Days FREE Trial $16M -0.3x -2.9x
CRSP Unlock Forecast - 30 Days FREE Trial $6048M -12.1x 3.5x
CVM Unlock Forecast - 30 Days FREE Trial $51M -0.9x 7.3x
DTIL Unlock Forecast - 30 Days FREE Trial $65M -2.2x 1.9x
ELUT Unlock Forecast - 30 Days FREE Trial $40M -1.4x -0.1x
ENGN Unlock Forecast - 30 Days FREE Trial $429M 3.7x 2.1x
ENTX Unlock Forecast - 30 Days FREE Trial $120M 8.5x 7.0x
ESLA Unlock Forecast - 30 Days FREE Trial $48M -3.1x -16.9x
EXEL Unlock Forecast - 30 Days FREE Trial $10592M 17.6x 5.2x
EXOZ Unlock Forecast - 30 Days FREE Trial $109M x 15.0x
FATE Unlock Forecast - 30 Days FREE Trial $194M -1.3x 0.7x
FDMT Unlock Forecast - 30 Days FREE Trial $497M -3.0x 1.2x
FENC Unlock Forecast - 30 Days FREE Trial $238M 1758.3x -39.7x
FNCH Unlock Forecast - 30 Days FREE Trial $20M -0.1x 1.4x
FTII Unlock Forecast - 30 Days FREE Trial $-26M x -0.7x
FTIIU Unlock Forecast - 30 Days FREE Trial $-26M x -0.8x
GILD Unlock Forecast - 30 Days FREE Trial $146370M 23.2x 7.4x
GLUE Unlock Forecast - 30 Days FREE Trial $832M 34.4x 3.1x
GNTA Unlock Forecast - 30 Days FREE Trial $59M x 4.8x
GPLB Unlock Forecast - 30 Days FREE Trial $M x x
HALO Unlock Forecast - 30 Days FREE Trial $7866M 14.1x 23.6x
HLVX Unlock Forecast - 30 Days FREE Trial $105M -0.6x 0.7x
HUMA Unlock Forecast - 30 Days FREE Trial $244M -3.3x 60.2x
IKT Unlock Forecast - 30 Days FREE Trial $145M -1.0x 1.8x
IMCR Unlock Forecast - 30 Days FREE Trial $1686M x 4.3x
IMVT Unlock Forecast - 30 Days FREE Trial $2957M -14.5x 4.9x
INBX Unlock Forecast - 30 Days FREE Trial $502M -6.8x 7.3x
INKT Unlock Forecast - 30 Days FREE Trial $56M -1.5x -1.4x
INMB Unlock Forecast - 30 Days FREE Trial $49M -2.5x 1.7x
INTS Unlock Forecast - 30 Days FREE Trial $8M -2.2x 3.7x
IOVA Unlock Forecast - 30 Days FREE Trial $737M -4.5x 1.1x
IPSC Unlock Forecast - 30 Days FREE Trial $49M -0.7x 0.2x
IVVD Unlock Forecast - 30 Days FREE Trial $211M -0.4x 4.9x
JSPR Unlock Forecast - 30 Days FREE Trial $39M -3.2x 1.7x
KLRS Unlock Forecast - 30 Days FREE Trial $83M x 1.6x
KLTO Unlock Forecast - 30 Days FREE Trial $31M x 2.9x
KOD Unlock Forecast - 30 Days FREE Trial $627M -2.5x 8.9x
KRYS Unlock Forecast - 30 Days FREE Trial $5448M 37.1x 5.2x
KYMR Unlock Forecast - 30 Days FREE Trial $4266M -17.8x 4.4x
KYTX Unlock Forecast - 30 Days FREE Trial $287M x 1.6x
LADX Unlock Forecast - 30 Days FREE Trial $M x x
LCTX Unlock Forecast - 30 Days FREE Trial $369M -4.7x 7.6x
LENZ Unlock Forecast - 30 Days FREE Trial $1154M -6.7x 5.6x
LIMN Unlock Forecast - 30 Days FREE Trial $0M x x
LXEO Unlock Forecast - 30 Days FREE Trial $445M -0.4x 3.2x
MAZE Unlock Forecast - 30 Days FREE Trial $1216M x 4.6x
MGX Unlock Forecast - 30 Days FREE Trial $107M x 0.6x
MRNA Unlock Forecast - 30 Days FREE Trial $10557M -3.2x 1.1x
NBIX Unlock Forecast - 30 Days FREE Trial $13614M 39.1x 5.1x
NMRA Unlock Forecast - 30 Days FREE Trial $305M -3.9x 1.7x
NVAX Unlock Forecast - 30 Days FREE Trial $1312M 3.1x 34.9x
PASG Unlock Forecast - 30 Days FREE Trial $27M -0.6x 0.7x
PCVX Unlock Forecast - 30 Days FREE Trial $5659M -20.4x 1.8x
PHGE Unlock Forecast - 30 Days FREE Trial $16M 1.5x 0.8x
PLUR Unlock Forecast - 30 Days FREE Trial $4M -1.4x -9.1x
PLX Unlock Forecast - 30 Days FREE Trial $183M 29.2x 3.7x
PRME Unlock Forecast - 30 Days FREE Trial $764M -1.5x 12.6x
PROK Unlock Forecast - 30 Days FREE Trial $184M x 0.0x
QGEN Unlock Forecast - 30 Days FREE Trial $10816M x 3.0x
QNCX Unlock Forecast - 30 Days FREE Trial $100M -1.7x 8.5x
RGNX Unlock Forecast - 30 Days FREE Trial $562M -1.8x 2.6x
RLAY Unlock Forecast - 30 Days FREE Trial $1134M -2.0x 1.7x
RXRX Unlock Forecast - 30 Days FREE Trial $2748M -4.7x 3.0x
SANA Unlock Forecast - 30 Days FREE Trial $1028M -2.1x 8.4x
SCNI Unlock Forecast - 30 Days FREE Trial $8720M -287.8x 1109.7x
SGMO Unlock Forecast - 30 Days FREE Trial $160M -1.6x 8.2x
SLXN Unlock Forecast - 30 Days FREE Trial $2M x 18.7x
SRZN Unlock Forecast - 30 Days FREE Trial $118M -0.5x 2.5x
STRO Unlock Forecast - 30 Days FREE Trial $68M -1.0x -2.5x
TARA Unlock Forecast - 30 Days FREE Trial $217M -2.1x 1.5x
TARS Unlock Forecast - 30 Days FREE Trial $3201M -12.4x 9.6x
TCBPY Unlock Forecast - 30 Days FREE Trial $15M x 13.6x
TCRX Unlock Forecast - 30 Days FREE Trial $287M -4.6x 1.6x
TECX Unlock Forecast - 30 Days FREE Trial $300M -8.9x 1.1x
TNYA Unlock Forecast - 30 Days FREE Trial $287M -2.5x 2.9x
TRML Unlock Forecast - 30 Days FREE Trial $1231M -3.5x 4.8x
TSHA Unlock Forecast - 30 Days FREE Trial $1385M -3.0x 5.6x
TVGN Unlock Forecast - 30 Days FREE Trial $138M x -29.3x
TWST Unlock Forecast - 30 Days FREE Trial $1856M -12.6x 3.9x
VACH Unlock Forecast - 30 Days FREE Trial $-1443M x 0.0x
VACHU Unlock Forecast - 30 Days FREE Trial $-1454M x 0.0x
VCEL Unlock Forecast - 30 Days FREE Trial $1753M 246.6x 5.7x
VIR Unlock Forecast - 30 Days FREE Trial $806M -2.0x 0.9x
VOR Unlock Forecast - 30 Days FREE Trial $3924M -0.6x 3.9x
VXRT Unlock Forecast - 30 Days FREE Trial $80M -0.9x 2.4x
VYGR Unlock Forecast - 30 Days FREE Trial $293M 570.6x 1.2x
ZIVO Unlock Forecast - 30 Days FREE Trial $50M -31.3x -2.0x

Frequently Asked Questions - Voyager Therapeutics, Inc. Stock Forecast

How accurate are Voyager Therapeutics, Inc. stock predictions?

Our AI model demonstrates 57% historical accuracy for VYGR predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence Voyager Therapeutics, Inc. stock price forecasts?

Our analysis considers Voyager Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Voyager Therapeutics, Inc. a good investment in 2025?

Based on our AI analysis, Voyager Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Voyager Therapeutics, Inc. forecasts updated?

Voyager Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Voyager Therapeutics, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Voyager Therapeutics, Inc. stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...